SciClone Pharmaceuticals (Holdings) Limited
SciClone Pharmaceuticals (Holdings) Limited, headquartered in China, is a prominent player in the biopharmaceutical industry, specialising in the development and commercialisation of innovative therapies. Founded in 1995, the company has made significant strides in addressing unmet medical needs, particularly in oncology and infectious diseases. With a strong operational presence in Asia and expanding into global markets, SciClone is renowned for its flagship product, ZADAXIN, a thymosin alpha 1 therapy that enhances immune response. This unique offering positions the company as a leader in immunotherapy, catering to both patients and healthcare providers. SciClone's commitment to research and development, coupled with strategic partnerships, has solidified its market position, making it a key contributor to the advancement of biopharmaceutical solutions. The company continues to focus on delivering high-quality, effective treatments that improve patient outcomes worldwide.
DitchCarbon Score
How does SciClone Pharmaceuticals (Holdings) Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SciClone Pharmaceuticals (Holdings) Limited's score of 24 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
SciClone Pharmaceuticals (Holdings) Limited's reported carbon emissions
In 2022, SciClone Pharmaceuticals (Holdings) Limited reported total carbon emissions of approximately 17,179,520 kg CO2e, comprising 5,031,790 kg CO2e from Scope 1 emissions and 12,147,730 kg CO2e from Scope 2 emissions. This data reflects the company's global operations. In 2021, the company reported total emissions of about 9,385,520 kg CO2e, with 117,100 kg CO2e from Scope 1 and 9,268,410 kg CO2e from Scope 2. The company has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. Notably, there are no specific reduction targets or climate pledges outlined in their current commitments, suggesting that while emissions data is available, formalised climate action strategies may still be in development. Overall, SciClone Pharmaceuticals' emissions data highlights significant greenhouse gas outputs, particularly from energy consumption, which is common in the pharmaceutical industry. The absence of reduction initiatives or targets may reflect an opportunity for the company to enhance its sustainability efforts and align with industry best practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 117,100 | 0,000,000 |
| Scope 2 | 9,268,410 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SciClone Pharmaceuticals (Holdings) Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
